Inhibrx Biosciences

Yahoo Finance • 7 days ago

Inhibrx gains as Stifel issues new Buy based on lead assets

[Wall Street New York stock exchange stock market] alexsl Inhibrx Biosciences (INBX [https://seekingalpha.com/symbol/INBX]) traded higher on Wednesday after Stifel launched its coverage of the cancer drug developer with a Buy recommendati... Full story

Yahoo Finance • 7 days ago

Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Deere (DE) to Hold... Full story

Yahoo Finance • 8 months ago

Countdown To October: Inhibrx Awaits Ozekibart Clinical Data

(RTTNews) - Inhibrx Biosciences Inc. (INBX) has a key catalyst to watch in October involving one of its clinical drug candidates, Ozekibart. Ozekibart, formerly known as INBRX-109, is a precision-engineered, tetravalent death receptor 5 (... Full story

Yahoo Finance • 8 months ago

Inhibrx Biosciences GAAP EPS of -$1.85, revenue of $1.3M

* Inhibrx Biosciences press release [https://seekingalpha.com/pr/20200152-inhibrx-reports-second-quarter-2025-financial-results] (NASDAQ:INBX [https://seekingalpha.com/symbol/INBX]): Q2 GAAP EPS of -$1.85. * Revenue of $1.3M. *   MO... Full story

Yahoo Finance • 9 months ago

Noteworthy Tuesday Option Activity: INBX, ODP, AZO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Inhibrx Biosciences Inc (Symbol: INBX), where a total volume of 679 contracts has been traded thus far today, a contract... Full story

Yahoo Finance • 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

SAN DIEGO, April 26, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has initiated a registr... Full story